Roswell Park opens clinical trial of promising brain cancer immunotherapy

Roswell Park Comprehensive Cancer Center is the first center to treat patients in a newly opened advanced-stage clinical trial utilizing the brain cancer vaccine SurVaxM, offering a new treatment option for patients who are dealing with a rare but deadly form of the disease. The multicenter randomized clinical trial is sponsored by MimiVax LLC, a company spun off from Roswell Park in 2012.

Currently recruiting, the phase 2B randomized SURVIVE trial is open to newly diagnosed adult glioblastoma patients. At Roswell Park, the trial will be under the direction of principal investigator, physician Ajay Abad, a neurologic oncologist and faculty member in the department of neuro-oncology. Altogether, the trial is expected to be open across 15 sites in the United States and China.

Glioblastoma, though rare, is the most common primary brain cancer. Fast-growing and aggressive, the cancer is typically treated with surgery, chemotherapy and radiation, but frequently recurs within a year of initial treatment. Median survival for patient with standard therapy is 16 months.

SurVaxM, an immunotherapy developed at Roswell Park by physician Robert Fenstermaker and Michael Ciesielski, Ph.D, assistant professor of oncology, is now being developed by MimiVax. It is a unique treatment vaccine that targets survivin, a protein that helps cancer cells stay alive. A recent single-arm phase II study in 63 patients with newly diagnosed glioblastoma demonstrated significantly longer survival time for patients treated with SurVaxM, with 93.7% alive a year after diagnosis, compared to expected 65% survival based on historical studies.

“For years, we’ve struggled to move the needle as far as good treatment options for glioblastoma. Our hope is that SurVaxM will offer patients both longer survival and better quality of life,” says Abad. “To hopefully be on the precipice of meaningful progress against glioblastoma and to be able to possibly see my patients outside of the hospital — years after their diagnosis — would be incredible.”

“Glioblastoma is a notoriously aggressive and hard-to-treat cancer. We are encouraged by the results from our earlier studies and excited to bring this treatment option to more brain cancer patients at more centers,” says Fenstermaker.

casibom jojobet Casibom casibom giriş casibom casibom giriş CASİBOM holiganbet casibom casibom güncel giriş casibom güncel Casibom Casibom holiganbet holiganbet casibom güncel giriş jojobet jojobet giriş jojobet güncel giriş Casibom